Medications before surgery to slow ovarian cancer growth
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests whether giving two common medications before and after surgery can slow the growth of ovarian cancer. The medications may help reduce stress signals that could make cancer spread faster during surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 20 and 85 years old.
- You have been diagnosed with a high-grade ovarian epithelial cancer (the most common type).
- You are scheduled for surgery to remove the cancer, either as your first treatment or after chemotherapy.
- You are generally healthy enough for surgery (based on your doctor's assessment).
- You are not allergic to beta-blockers or NSAIDs (like ibuprofen).
- You do not have certain heart, lung, stomach, kidney, or other serious medical conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether giving two commonly used medicines before surgery—one that can lower stress on the body (a beta-blocker) and one that reduces inflammation (a COX-2 inhibitor)—can improve outcomes compared with standard care. It’s for people with advanced ovarian, fallopian tube, or primary peritoneal cancer who are having open surgery.
This trial tests adding propranolol (a heart medication) to standard chemotherapy before surgery for advanced high-grade serous ovarian cancer. The goal is to see if this combination helps shrink tumors more effectively.
This trial is testing a combination of two new immunotherapy drugs (iparomlimab and tuvonralimab) given before surgery and together with chemotherapy for advanced ovarian cancer. It aims to see if this approach can shrink the cancer more effectively and improve outcomes.
This trial checks whether having surgery to remove as much tumor as possible, followed by ongoing targeted treatment, helps people with advanced ovarian (and related) cancers live longer and/or control cancer better. It specifically uses tumor-testing results to match patients and then continues treatment after surgery.
This trial tests two investigational drug combinations (fluzoparib plus famitinib, or fluzoparib plus SHR-1701) given before surgery to shrink ovarian cancer. The goal is to see which approach helps more with tumor reduction and making surgery more effective.
This trial checks if adjusting the timing of surgery (interval debulking surgery) after chemotherapy can improve outcomes for people with advanced ovarian cancer. It's for those who cannot have surgery right away and will receive chemotherapy first.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.